Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12610000558022
ACTRN12610000558022
Active, not recruiting
未知

A prospective non-interventional study to evaluate the effect of Triptorelin Embonate (Diphereline (TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients.

Ipsen Pty Ltd0 sites70 target enrollmentJuly 12, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsocally advanced or metastatic prostate cancer with Lower Urinary Tract Symptoms (LUTS)Locally advanced or metastatic prostate cancer with Lower Urinary Tract Symptoms (LUTS)Cancer - ProstateRenal and Urogenital - Other renal and urogenital disorders

Overview

Phase
未知
Intervention
Not specified
Conditions
ocally advanced or metastatic prostate cancer with Lower Urinary Tract Symptoms (LUTS)
Sponsor
Ipsen Pty Ltd
Enrollment
70
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 12, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.The patient is suffering from locally\-advanced (at least Tumour 3 stage) or metastatic prostate cancer scheduled to receive Diphereline (TM) 11\.25mg.
  • •2\.The patient is presenting with moderate to severe LUTS ((lower urinary tract symptoms) IPSS score \>7\).

Exclusion Criteria

  • •1\.The patient has a risk of serious complication in the case of tumour flare (vertbral metastases threatening spinal cord compression or significant obstructive uropathy).
  • •2\.History of surgical castration.
  • •3\.History of urethral stricture.
  • •4\.Life expectancy of less than 12 months.
  • •5\.Has undergone surgery for the treatment of lower urinary tract symptoms(LUTS).
  • •6\.Therapy with a Luteinizing hormone\-releasing hormone (LHRH) analogue in the last 6 months.
  • •7\. Has received alpha receptor blockers in the last two weeks prior to the start of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A non-interventional, prospective study to evaluate change in physical activity, relationship satisfaction and psychological well-being in patients with rheumatoid arthritis after introduction of the JAK inhibitor filgotinib and also in their partners.M06.8Other specified rheumatoid arthritis
DRKS00032128Helios Fachklinik Vogelsang-Gommern, Rheumatologie40
Completed
Not Applicable
A retrospective non-interventional study evaluating retention rate of Everolimus as add-on epilepsy therapy in adult patients with tuberose sclerosisQ85.1Tuberous sclerosis
DRKS00020248Epilepsiezentrum Kork45
Completed
Not Applicable
A prospective, non-interventional study to investigate the effectiveness of a recombinant fusion protein linking coagulation Factor IX with recombinant albumin (rIX-FP) in patients with hemophilia BD67Hereditary factor IX deficiency
DRKS00015079CSL Behring GmbH73
Recruiting
Phase 4
Performance and safety evaluation of pelvic plate system fixation during fractures, fusions, andosteotomies of the acetabulum, sacrum, ilium, and entire pelvic ring, as well as treatment of sacroiliac jointHealth Condition 1: S329- Fracture of unspecified parts of lumbosacral spine and pelvis
CTRI/2023/06/053602Auxein Medical Pvt. Ltd
Completed
Not Applicable
A prospective non-interventional study to assess quality of life and COPDsymptoms in patients with COPD on LAMA/LABA/ICS triple therapy withElebrato® Ellipta®J44.9Chronic obstructive pulmonary disease, unspecified
DRKS00031897BERLIN-CHEMIE AG931